PROSTATE


Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Encyclopedia, Wikipedia.
Related to PROSTATE: prostate gland, Prostate exam
AcronymDefinition
PROSTATEPhysicians for Rational Ordering of Screening Tests And Therapeutic Effectiveness
References in periodicals archive ?
The report titled Global Prostate Cancer Therapeutics Market to 2020 provides a comprehensive assessment of the fast-evolving, high-growth of Prostate Cancer Therapeutics Market.
Global Prostate Cancer - Hormonal Therapy Drugs Sales & Forecast to 2020
Chi, Medical Oncologist at the Vancouver Prostate Center and the BC Cancer Agency, and the Principal Investigator for the study.
Preliminary results from three Phase 1 clinical trials show that OGX-011 is well tolerated, achieves excellent drug concentrations in prostate tissue, and produces a 91 percent dose-dependent down-regulation of clusterin in prostate cancer cells removed from prostate cancer patients.
The experiment showed that, consistent with malignant cell growth, prostate cells chronically exposed to arsenic grew more rapidly than control cells in both media.
The researchers recruited nearly 700 men who had just been diagnosed with prostate tumors, were less than 75 years old, and were healthy enough, aside from the cancer, to live at least 10 more years.
Two of the four men in the Rams' ``Fearsome Foursome'' survived prostate cancer, and Grier wants to let people know about the foundation's research efforts.
The odds of surviving prostate cancer for five years are 98 percent, up from 67 percent in the mid-1970s.
New research shows that men with the highest blood levels of vitamin E were five times less likely to develop prostate cancer.
PSMA is a protein abundantly expressed on the surface of prostate cancer cells, with an increased expression in high-grade cancers, metastatic disease and hormone-refractory prostate cancer.
Annualized US prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
Prostate cancer is the second leading cause of cancer death in American men (Crawford 2003).